MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers

MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers

Chemo-resistance is an important barrier to effective treatment of ovarian cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors are currently promising targeted drugs used to treat BRCA-mutant ovarian cancer. Ovarian cancer patients with BRCA 1/2 mutations appear to benefit better from PARP inhibi...

Full description

Bibliographic Details
Main Authors: Yue Sun, Jing Wu, Xiaoying Dong, Jingzi Zhang, Chao Meng, Guoyan Liu
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Translational Oncology
Subjects:
miR-506-3p
PARP inhibitors
Chemo-resistance
Ovarian cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304794

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320304794

Similar Items